US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

7.21

-1.0500-12.71%

Pre-market: 7.01-0.2000-2.77%06:45 EDT

Volume:1.53M

Turnover:11.08M

Market Cap:261.67M

PE:-2.76

High:8.30

Open:8.25

Low:6.99

Close:8.26

52wk High:33.20

52wk Low:6.99

Shares:36.29M

Float Shares:19.98M

Volume Ratio:2.05

T/O Rate:7.63%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:0.94

PE(LYR):-0.64

Loading ...

Overview Company News Filings

Evommune Scraps Eczema Drug After Trial Miss, Shares Plunge

Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints

Evommune down 31% at $9 after Phase 2b EVO-756 study results

Evommune Says Evo756 Misses Endpoints in Phase 2b Atopic Dermatitis Trial

Evommune, - Has Balance Sheet Supporting Operations into 2029

THOMSON REUTERS

Evommune, Inc.: to Continue Phase 2B Development of Evo756 in Migraine Prophylaxis

THOMSON REUTERS

Evommune, - Phase 2B Trial Enrolled 121 Adults; Primary and Secondary Endpoints not Met

THOMSON REUTERS

Evommune, - Evo301 to Enter Phase 2B Trial in Atopic Dermatitis in Mid-2027

THOMSON REUTERS

U.S. Stocks on the MOVE-Williams-Sonoma, Kraft Heinz, Evommune

Needham Starts Coverage on Evommune; Shares Gain

Evommune Shares up 1.7% as Needham Starts Coverage

THOMSON REUTERS

Evommune Shares up 4.2% Premarket as Needham Starts Coverage with Buy Rating

THOMSON REUTERS

Needham Initiates Evommune at Buy With $28 Price Target

MT Newswires Live

Evommune, Inc. : Needham Initiates Coverage with Buy Rating; Target Price $28

THOMSON REUTERS

Evommune Price Target Announced at $28.00/Share by Needham

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Evommune price target lowered to $29 from $30 at RBC Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/EVMN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":7.21,"timestamp":1790884800000,"preClose":8.26,"halted":0,"volume":1525172,"hourTrading":{"tag":"盘前","latestPrice":7.01,"preClose":7.21,"latestTime":"06:45 EDT","volume":926,"amount":6475.1723242,"timestamp":1790937927433,"change":-0.2,"changeRate":-0.027739,"amplitude":0.004133},"delay":0,"changeRate":-0.1271186440677966,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Pre-Mkt","change":-1.05,"latestTime":"10-02 06:54:03 EDT","open":8.25,"high":8.3,"low":6.99,"amount":11075769.323146,"amplitude":0.158596,"askPrice":7.86,"askSize":100,"bidPrice":6.41,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":7.21,"preHourTrading":{"tag":"盘前","latestPrice":7.01,"preClose":7.21,"latestTime":"06:45 EDT","volume":926,"amount":6475.1723242,"timestamp":1790937927433,"change":-0.2,"changeRate":-0.027739,"amplitude":0.004133},"postHourTrading":{"tag":"盘后","latestPrice":7.2,"preClose":7.21,"latestTime":"19:40 EDT","volume":29965,"amount":215232.8508,"timestamp":1790898004365,"change":-0.01,"changeRate":-0.001387,"amplitude":0.059639},"volumeRatio":2.0461637617406634,"impliedVol":0.8852,"impliedVolPercentile":0.3214},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":2.0461637617406634,"shares":36292113,"dividePrice":0,"high":8.3,"amplitude":0.158596,"preClose":8.26,"low":6.99,"week52Low":6.99,"pbRate":"0.94","psRate":"26.17","week52High":33.2,"institutionHeld":0,"latestPrice":7.21,"eps":-2.609,"divideRate":0,"volume":1525172,"delay":0,"ttmEps":-2.609,"open":8.25,"prevYearClose":17.12,"prevWeekClose":8.49,"prevMonthClose":8.26,"prevQuarterClose":8.26,"fiveDayClose":8.8,"twentyDayClose":12.48,"sixtyDayClose":13.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787803200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-10-01","current":-2.763511,"percent":1,"low":-16.229076,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"high":-3.16657,"avg":-9.281325,"sd":3.229597,"marketCap":299772853},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-09-04","current":-4.600344,"twenty":-12.384421,"median":-9.710846,"eighty":-6.276801,"marketCap":435505356},{"date":"2026-09-11","current":-4.048303,"twenty":-12.366639,"median":-9.695292,"eighty":-6.160195,"marketCap":383244713},{"date":"2026-09-18","current":-3.592102,"twenty":-12.358271,"median":-9.618094,"eighty":-5.832183,"marketCap":340057098},{"date":"2026-09-25","current":-3.373586,"twenty":-12.336306,"median":-9.537021,"eighty":-5.714629,"marketCap":319370594},{"date":"2026-10-01","current":-3.16657,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"marketCap":299772853}],"updateTime":1790938443124},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666308876","title":"Evommune Scraps Eczema Drug After Trial Miss, Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308876","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308876?lang=en_us&edition=fundamental","pubTime":"2026-09-09 06:17","pubTimestamp":1788905828,"startTime":"0","endTime":"0","summary":"Evommune scraps eczema drug after trial miss, shares plungeSept 8 -EvommuneEVMN.Nsaid on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.Here are some detailsThe company said its drug, EVO756, did notshow a meaningful percent change in a scale that measures the severity of eczema when tested in patients with atopic dermatitis.Atopic dermatitis is a chronic, inflammatory skin condition that causes dry, red,itchy and irritatedpatches of skin.The trial enrolled 121 adults with moderate-to-severeatopic dermatitisover a 12-week treatment period, with follow-up through week 14.Evommune said the drug did not meet the primary or secondary goals in any of the doses studied.The company said it will continue to develop EVO756 for migraine prevention.\"EVO756 was generally well tolerated with a safety profile consistent with prior studies, supporting its continued evaluation","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4501OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666707253","title":"Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2666707253","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666707253?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:50","pubTimestamp":1788904212,"startTime":"0","endTime":"0","summary":"Evommun “announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-phase-2b-ev0756-trial-did-not-meet-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-phase-2b-ev0756-trial-did-not-meet-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666700333","title":"Evommune down 31% at $9 after Phase 2b EVO-756 study results","url":"https://stock-news.laohu8.com/highlight/detail?id=2666700333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666700333?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:50","pubTimestamp":1788904207,"startTime":"0","endTime":"0","summary":"17:46 EDT Evommune (EVMN) down 31% at $9 after Phase 2b EVO-756 study results Published first on TheFly – the ultimate source for real-time, market...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-down-31-at-9-after-phase-2b-evo-756-study-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-down-31-at-9-after-phase-2b-evo-756-study-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","EVO","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370210","title":"Evommune Says Evo756 Misses Endpoints in Phase 2b Atopic Dermatitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370210","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370210?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903808,"startTime":"0","endTime":"0","summary":"Evommune says EVO756 misses endpoints in Phase 2b atopic dermatitis trialEvommune posted top-line results from a Phase 2b trial of oral EVO756 in adults with moderate-to-severe atopic dermatitis.The s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4xVr3d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370219","title":"Evommune, - Has Balance Sheet Supporting Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370219?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666297370","title":"Evommune, Inc.: to Continue Phase 2B Development of Evo756 in Migraine Prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666297370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666297370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666213370","title":"Evommune, - Phase 2B Trial Enrolled 121 Adults; Primary and Secondary Endpoints not Met","url":"https://stock-news.laohu8.com/highlight/detail?id=2666213370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666213370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666037029","title":"Evommune, - Evo301 to Enter Phase 2B Trial in Atopic Dermatitis in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666037029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666037029?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1N9QMB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662374610","title":"U.S. Stocks on the MOVE-Williams-Sonoma, Kraft Heinz, Evommune","url":"https://stock-news.laohu8.com/highlight/detail?id=2662374610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662374610?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:40","pubTimestamp":1787766046,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, EvommuneAugust 26 (Reuters)-Wall Street's main indexes were subdued on Wednesday after a key inflation reading came in hotter than expected, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL6N44N0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KHC","LU0162691827.USD","LU0321505439.SGD","LU0942090050.USD","LU0868494708.USD","LU0211331839.USD","BK4178","LU0306806265.USD","BK4588","BK4558","BK4585","EVMN","WSM","BK4139","LU0208291251.USD","BK4504","BK4212","LU0225284248.USD","LU0225771236.USD","LU0320765489.SGD","LU0868494617.USD","LU0072461881.USD","LU1699723380.USD","LU0985481810.HKD","LU0306807586.USD","LU0070302665.USD","LU1571399168.USD","BK4559","FTXG","LU0321505868.SGD","LU0170899867.USD","LU0006061336.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745963","title":"Needham Starts Coverage on Evommune; Shares Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745963","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745963?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:32","pubTimestamp":1787761969,"startTime":"0","endTime":"0","summary":"BUZZ-Needham starts coverage on Evommune; shares gain** Shares of drug developer EvommuneEVMN.Nrise 1.7% to $14.02** Needham starts coverage on EVMN with \"buy\" rating and $28 PT** Says rating based on co's \"promising I&I pipeline, notably EVO301, an IL-18 inhibitor fusion protein, that has demonstrated proof-of-concept efficacy on par  vs. current biologics for atopic dermatitis \"** Adds \"upcoming Sept readout of the ph 2b trial in AD could generate significant shareholder value\"** EVMN has lost over 18% since its debut in November last year","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712283","title":"Evommune Shares up 1.7% as Needham Starts Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662712283?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:38","pubTimestamp":1787751482,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0NG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662785715","title":"Evommune Shares up 4.2% Premarket as Needham Starts Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2662785715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662785715?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:42","pubTimestamp":1787744561,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715570","title":"Needham Initiates Evommune at Buy With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715570?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:29","pubTimestamp":1787743781,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) has an average rating of buy and mean price target of $29.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713360","title":"Evommune, Inc. : Needham Initiates Coverage with Buy Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662713360?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:06","pubTimestamp":1787742403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718146","title":"Evommune Price Target Announced at $28.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718146?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:57","pubTimestamp":1787741820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989427","title":"U.S. Research Roundup- Intuit, MongoDB, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989427","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989427?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:57","pubTimestamp":1787727427,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Intuit, MongoDB, ZscalerAug 26 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Intuit, MongoDB and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DKS","MRVL","INTU","BOX","SOXY","CTEC","FDTX","APP","FIVE","AXGN","EPAM","WCLD","GDDY","ADIG","CNR","STYL","SNOU","RBRK","OLLI","MRNX","GPN","EVMN","DELL","FROG","NKE","CHWY","AMR","LHX","ASB","JAZZ","AFRM","SMTC","GTLB","FIS","AMRX","NEOG","SNOW","MDB","CPRT","LSCC","CAKE","FSLR","NCNO","SMOG","MRVU","AIS","FRNW","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150197","title":"Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150197?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:40","pubTimestamp":1786628434,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BitGo Holdings, Inc. Class A (BTGO) and Evommune, Inc. (EVMN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BTGO","EVMN","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931856","title":"Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931856","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931856?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365951,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. today and set a price target of $22.00. Clark-Gartner covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646812","title":"RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646812?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:46","pubTimestamp":1786106799,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) has an average rating of buy and mean price target of $32.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657453676","title":"Evommune price target lowered to $29 from $30 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657453676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657453676?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:21","pubTimestamp":1786105261,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Evommune (EVMN) to $29 from $30 and keeps an Outperform rating on the shares. Despite the stock’s re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":106,"code":"91000000","status":"200"}]}}